Cancer chemotherapy treatment protocols:
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Buch |
| Sprache: | English French |
| Veröffentlicht: |
Oxford [u.a.]
Blackwell Science
1998
|
| Schlagworte: | |
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | X, 145 S. |
| ISBN: | 0865426937 |
Internformat
MARC
| LEADER | 00000nam a2200000 c 4500 | ||
|---|---|---|---|
| 001 | BV011642285 | ||
| 003 | DE-604 | ||
| 005 | 19980805 | ||
| 007 | t | ||
| 008 | 971121s1998 |||| 00||| eng d | ||
| 020 | |a 0865426937 |9 0-86542-693-7 | ||
| 035 | |a (OCoLC)36470678 | ||
| 035 | |a (DE-599)BVBBV011642285 | ||
| 040 | |a DE-604 |b ger |e rakddb | ||
| 041 | 1 | |a eng |h fre | |
| 049 | |a DE-29 | ||
| 050 | 0 | |a RC271.C5 | |
| 082 | 0 | |a 616.99/4061 |2 21 | |
| 084 | |a XH 3200 |0 (DE-625)152888:12905 |2 rvk | ||
| 100 | 1 | |a Khayat, David |d 1956- |e Verfasser |0 (DE-588)11361442X |4 aut | |
| 245 | 1 | 0 | |a Cancer chemotherapy treatment protocols |c David Khayat ; Jonathan Waxman ; Eric-Charles Antoine |
| 264 | 1 | |a Oxford [u.a.] |b Blackwell Science |c 1998 | |
| 300 | |a X, 145 S. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 650 | 4 | |a Antineoplastic Agents |x administration & dosage | |
| 650 | 4 | |a Antineoplastic agents |x Administration | |
| 650 | 4 | |a Cancer |x Chemotherapy | |
| 650 | 4 | |a Neoplasms |x drug therapy | |
| 650 | 0 | 7 | |a Chemotherapie |0 (DE-588)4127083-6 |2 gnd |9 rswk-swf |
| 689 | 0 | 0 | |a Chemotherapie |0 (DE-588)4127083-6 |D s |
| 689 | 0 | |5 DE-604 | |
| 700 | 1 | |a Waxman, Jonathan |e Verfasser |4 aut | |
| 700 | 1 | |a Antoine, Eric-Charles |e Verfasser |4 aut | |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007846354&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-007846354 | ||
Datensatz im Suchindex
| _version_ | 1804126175116656640 |
|---|---|
| adam_text | Contents
Preface,ix
General Principles, 1
Classification of Antitumour Agents
and Abbreviations, 9
Chemotherapy Protocols for
Specific Tumours
Breast Cancer, 13
Cyclophosphamide, methotrexate, 5 fluorouracil
(CMF),13
Adriamycin, cyclophosphamide (AC), 14
Cyclophosphamide, adriamycin, 5 fluorouracil (CAF),
15
Adriamycin, mitomycin C, vincristine, 5 fluorouracil
(FOAM), 15
Adriamycin, mitomycin C, vincristine (VAM), 16
Carboplatin, 5 fluorouracil, folinic acid (CARBO
FUFOL),16
Carboplatin, etoposide (CBDCA VP16), 17
5 Fluorouracil, mitozantrone, cyclophosphamide
(FNQ.17
5 Fluorouracil, adriamycin, cyclophosphamide (FAC),
18
5 Fluorouracil, epirubicin, cyclophosphamide (FEC),
18
Paclitaxel, 5 fluorouracil, folinic acid (PFF1), 19
Paclitaxel, 5 fluorouracil, folinic acid (PFF2), 19
Paclitaxel, epirubicin (PE), 20
Paclitaxel, doxorubicin(PDI), 21
Paclitaxel, doxorubicin (PD2), 21
Docetaxel, cisplatin (DC1), 22
Oocetaxel, doxorubicin, cyclophosphamide (TAC), 22
Docetaxel, vinorelbine (DV), 23
Docetaxel, doxorubicin (DD), 23
Docetaxel, cyclophosphamide (DC2), 24
Docetaxel, 5 fluorouracil (DF), 24
Vinorelbine, 5 fluorouracil (VF), 25
Vinorelbine, doxorubicin (VD), 25
Gynaecological Cancers, 27
Ovarian adenocarcinoma, 27
Adriamycin, cyclophosphamide (AC), 27
Cisplatin, adriamycin, cyclophosphamide (PAC), 28
Carboplatin(CBDCA),28
Carboplatin, adriamycin, cyclophosphamide (CAC),
29
Cisplatin, carboplatin (CDDP CBDCA), 30
Carboplatin, hexamethylmelamine, adriamycin,
cyclophosphamide (CHAC), 30
Adriamycin, cisplatin, cyclophosphamide,
hexamethylmelamine (CHAD), 31
Adriamycin, cisplatin, cyclophosphamide,
hexamethylmelamine (CHAP 5), 31
Cisplatin, cyclophosphamide, hexamethylmelamine,
5 fluorouracil(CHEX UP),32
Carboplatin, cisplatin, ifosfamide (CIC), 33
Cisplatin, cyclophosphamide (CP), 33
Carboplatin, cyclophosphamide (CPA), 34
Paditaxel, cisplatin (PC), 34
Topotecan (TPT), 35
Adenocarcinoma of the cervix, 36
Bleomycin, cisplatin, methotrexate, vincristine
(BCVM),36
Bleomycin, ifosfamide, carboplatin (BIC), 37
Bleomycin, cisplatin, mitomycin, vincristine
(BOMP),37
Adriamycin, cisplatin, 5 fluorouracil (FAP), 38
Bleomycin, cisplatin, methotrexate (MBC), 38
Endometrial adenocarcinoma, 40
Adriamycin, cyclophosphamide, vincristine, 5
fluorouracil (CAFV), 40
Adriamycin, cisplatin, cyclophosphamide (CAP), 41
Adriamycin, cyclophosphamide, megestrol acetate
(MCA), 41
Choriocarcinoma, 43
Actinomycin D, folinic acid, cyclophosphamide,
etoposide, methotrexate, vincristine (EMA CO), 43
Cisplatin, methotrexate, vincristine (CVM), 44
Genito urinary Cancers, 45
Non seminomatous germ cell tumours, 45
Bleomycin, cisplatin, etoposide (BEP), 45
Carboplatin, etoposide, bleomycin (CEB), 46
Carboplatin, etoposide (CE), 46
Carboplatin, etoposide, bleomycin (CEB), 47
Bleomycin, cisplatin, etoposide, vinblastine
(PVeBV),47
V
Vi CONTENTS
Adinomydn D, Weomycin, dspiatin,
cydophosphafrade,vinblastine(VAB^),48
Cisptatin. vinblastine, tfosfemide (VelP), 49
Cisptatin. etoposide, Hosfamide (VIP), 49
Cisplatin, vincristine, methotrexate, Weomycin,
actinomydn D, etoposide (POMBACE), SO
Bladder cancer, 52
Cisplatin, cycJophosphamide, adriamydn (CISCA),
52
Cisplatin, methotrexate, vinblastine (CMV), 53
Epirubicin, carboplatin (ECb), 53
Adriamydn, cydopnosphamide, methotrexate
(MAC), 54
Carboplatin, methotrexate, vinblastine (M CA VI),
55
Methotrexate, vinUastine, doxorubidn, dspiatin
(M VAQ.55
Methotrexate, vinblastine, epirubicin, carboplatin
(M VECA),56
MKozantrone, vinblastine, methotrexate, carboplatin
(MVMJ),57
Paditaxel, cisplatin (K1), 57
Padrtaxe), carboplatin (PJ1), 58
Paditaxel, carboplatin (PJ2), 58
Cisplatin, gemcitabine (CGI), 59
Cisplatin, gemcitabine (CG2), 59
Prostatic adenocardnoma, 61
Mitozantrone, prednisone (MP), 61
Adriamydn, cydophosphamide, methotrexate
(CAM), 62
Adriamydn, dspiatin (CD), 62
Adriamydn, cydophosphamide, 5 fluorouradl
(CDF), 63
Renal cell cancer, 64
lnterleukin 2, interfere*! a (I2la), 64
lnterieukin 2, interfere* a, 5 fluorouradl (115), 64
Gastrointestinal Cancers, 66
Gastric cancer, 66
Etoposide, doxorubidn, cisplatin (EAP), 66
Adriamydn, methotrexate, 5 fluorouracil, foJinic acid
(FAMTX),67
Epirubicin, cisplatin, 5 fluorouradl (ECF), 67
5 Fluorouracil, doxorubidn, dspiatin (FAP), 68
Pancreatic cancer, 69
Adriamydn, mitomycin C, streptozotodn, 5
fluorouradl(FAM S),69
Adriamydn, cisplatin, 5 fluorouradl (FAP 2), 70
Mitomycin C, streptozotodn, 5 fluorouradl
(FSM),70
Gemdtabine(GEM),71
Cokmctal tumours, 72
5 Fluorouradl, folinic add (De Gramont regimen), 72
5 Fluorouradl. folinic add (Mayo Clinic regimen), 73
5 Fluorouradl, folinic add (Machover regimen), 73
Oxaliplatin, 5 fluorouradl, folinic add (FOLFOX2),
74
CPT 11,5 fluorouradl, folinic add (CFF), 74
Oxaliplatin, CPT H(OC), 75
CPT 11,5 fluorouradl, folinic acid (LV5FU2) 76
Bone and Soft Tissue Sarcomas, 77
Soft tissue sarcomas, 77
Adriamydn, dacarbazine (AD), 77
Adriamycin, cydophosphamide, dacarbazine (CAD),
78
Adriamydn, cydophosphamide, dacarbazine,
vincristine (CY VA DIQ, 78
Adriamycin, cydophosphamide, cisplatin,
dacarbazine, vindesine (DCPAV), 79
Etoposide, ifosfamide (El), 79
Adriamycin, ifosfamide (IA), 80
Adriamydn, dacarbazine, ifosfamide, MESNA
(MAID), 81
Cisplatin, ifosfamide (PI), 81
Adriamycin, cydophosphamide, vindesine (VAC),
82
Cydophosphamide, cisplatin, tomustine, vindesine
(VCPO.82
High dose ifosfamide (hd IFO), 83
Osteosarcoma, 84
Adriamydn, cisplatin (AC), 84
Methotrexate, folinic acid, bleomycin,
cydophosphamide, actinomycin D, adriamycin
(T 10),85
Folinic acid, methotrexate, vincristine, adriamycin
(VLM),85
Folinic acid, methotrexate, vincristine (VMC), 86
Ewing s sarcoma, 87
Adriamycin, methotrexate, cydophosphamide,
actinomycin 0, bleomycin, vincristine (T 9), 87
Actinomycin D, cydophosphamide, vincristine
(VAC), 88
Lung Cancers, 89
Small cell lung cancer, 89
Adriamycin, cydophosphamide, etoposide
(CAE),89
Adriamydn, cydophosphamide, vincristine
(CAV%90
Carboplatin, ifosfamide (CBDCA I), 90
Carboplatin, etoposide, ifosfamide (CEI), 91
Carboplatin. epirubicin, etoposide (CEV), 91
Cisplatin, cyclophosphamide, etoposide (CEP),
92
Carboplatin, vinblastine, methotrexate (CVM), 93
Adriamycin, cyclophosphamide, etoposide,
vincristine(EVAC),93
Ifosfamide, etoposide (IE), 94
Cisplatin, etoposide (EP), 94
Etoposide (VP16), 95
Non small cell lung cancer, %
Cisplatin, mitomycin C, vindesine (MVP), 96
Carboplatin, etoposide (CE), 97
Cisplatin, etoposide (EP), 97
Adriamycin, cyclophosphamide, lomustine,
methotrexate (MACC), 98
Adriamycin, cyclophosphamide, methotrexate,
procarbazine (CAMP), 98
Cisplatin, etoposide, vindesine (ELETOP), 99
5 Fluorouracil, mitomycin C, vindesine (Fe Mi), 100
Cisplatin, etoposide, ifosfamide (ICE), 100
Mitomycin C, ifosfamide, carboplatin (MICb), 101
Adriamycin, cisplatin, cyclophosphamide
(PAQ.101
Cisplatin, vindesine (CV), 102
Cisplatin, vinorelbin (CVNB), 103
Mitomycin C, ifosfamide. cisplatin (MIC), 103
Gemcitabine(GEM),104
Paclitaxel, carboplatin (PJ), 104
Cisplatin, gemcitabine (CG1), 105
Cisplatin, gemcitabine (CG2), 106
Mesothelioma, 107
Adriamycin, cisplatin (AP), 107
Adriamycin, cyclophosphamide (AC), 107
Skin Cancers, 109
Malignant melanoma, 109
Bleomycin, dacarbazine, lomustine, vindesine
(BELD).1O9
Bleomycin, dacarbazine, lomustine, vincristine
(BOLD), 110
Cisplatin, dacarbazine, vindesine (CDV), 110
Dacarbazine, fotemustin, vindesine (FDV), 111
Cisplatin, dacarbazine, vinblastine (DVP), 112
Lomustine, procarbazine, vincristine (POC), 112
Vindesine (VDS), 113
Dacarbazine, interferon a (DTIC IFN a), 113
Cisplatin, interleukin 2, interferon a
(Pi2), 114
CONTENTS vii
Head and Neck Cancers, 115
Squamous cell carcinoma of the head and neck, 115
Bleomycin, cisplatin, methotrexate, 5 fluorouracil
(BCMF),115
Carboplatin, 5 fluorouracil (FC), 116
Bleomycin, cisplatin, methotrexate, folinic acid
(MCB),116
Bleomycin, cisplatin, methotrexate, vincristine
(COMB), 117
Bleomycin, cisplatin, mitomycin C (BMC), 117
Cisplatin, 5 fluorouracil (CF), 118
Bleomycin, cisplatin, methotrexate (MBD), 119
Cisplatin, 5 fluourouracil, folinic acid (PFL), 119
Bleomycin, cisplatin, vinblastine (VBC), 120
Lymphomas, 121
Non Hodgkin s lymphoma, 121
Low grade, 121
High grade, 121
Adriamycin, cyclophosphamide, prednisone,
vincristine (CHOP), 121
Adriamycin, bleomycin, cyclophosphamide,
prednisone, vincristine (BACOP), 122
Adriamycin, bleomycin, cyclophosphamide,
prednisone, procarbazine, vincristine (CAP BOP),
123
Adriamycin, cyclophosphamide, vincristine,
methotrexate, cytarabine, folinic acid (ACOMLA),
123
Adriamycin, bleomycin, cyclophosphamide,
prednisone, vincristine (CHOP Bleo), 124
Adriamycin, cyclophosphamide, prednisone,
procarbazine, vincristine (CHOP P), 125
Cyclophosphamide, prednisone, procarbazine,
vincristine (C MOPP), 125
Folinic acid, cyclophosphamide, cytarabine,
methotrexate, vincristine (COMLA), 126
Adriamycin, bleomycin, cyclophosphamide,
prednisone, procarbazine, vincristine (COP
BLAM),126
Cyclophosphamide, prednisone, procarbazine,
vincristine (COPP), 127
Cyclophosphamide, prednisone, vincristine
(CVP),128
Adriamycin, bleomycin, cyclophosphamide,
cytarabine, etoposide, methotrexate, prednisone,
vincristine (Pro mACE Cyta BOM), 128
Adriamycin, cyclophosphamide, etoposide,
methotrexate, mustine, prednisone, procarbazine,
vincristine (Pro MACE MOPP), 129
Viii CONTENTS
Adriamycin, bleomycin, cyclophosphamide,
dexamethasone, methotrexate, vincristine (m
BACOD),130
Hodgkin s disease, 131
Adriamycin, bleomycin, vinblastine, dacarbazine
(ABVD),131
Adriamycin, bleomycin, dacarbazine, lomustine,
prednisone(ABDIC),132
Adriamycin, bleomycin, lomustine, vinblastine (B
CAVE),132
Camnustine, cyclophosphamide, prednisone,
procarbazine, vinblastine (BVCPP), 133
Cyclophosphamide, lomustine, prednisone,
procarbazine, vinblastine (CVCPP), 134
Lomustine, prednisone, procarbazine, vinblastine
(CVPP),134
Mechlorethamine, prednisone, procarbazine,
vincristine(MOPP),135
Adriamycin, bleomycin, mechlorethamine,
prednisone, procarbazine, vincristine, vinblastine
(MOPP ABV HYBRID),136
Adriamycin, bleomycin, mechlorethamine,
prednisone, vincristine (MOP BAP), 136
Adriamycin, bleomycin, lomustine, streptozocine
(SCAB), 137
Index, 139
|
| any_adam_object | 1 |
| author | Khayat, David 1956- Waxman, Jonathan Antoine, Eric-Charles |
| author_GND | (DE-588)11361442X |
| author_facet | Khayat, David 1956- Waxman, Jonathan Antoine, Eric-Charles |
| author_role | aut aut aut |
| author_sort | Khayat, David 1956- |
| author_variant | d k dk j w jw e c a eca |
| building | Verbundindex |
| bvnumber | BV011642285 |
| callnumber-first | R - Medicine |
| callnumber-label | RC271 |
| callnumber-raw | RC271.C5 |
| callnumber-search | RC271.C5 |
| callnumber-sort | RC 3271 C5 |
| callnumber-subject | RC - Internal Medicine |
| classification_rvk | XH 3200 |
| ctrlnum | (OCoLC)36470678 (DE-599)BVBBV011642285 |
| dewey-full | 616.99/4061 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 616 - Diseases |
| dewey-raw | 616.99/4061 |
| dewey-search | 616.99/4061 |
| dewey-sort | 3616.99 44061 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01558nam a2200409 c 4500</leader><controlfield tag="001">BV011642285</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">19980805 </controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">971121s1998 |||| 00||| eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">0865426937</subfield><subfield code="9">0-86542-693-7</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)36470678</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV011642285</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="1" ind2=" "><subfield code="a">eng</subfield><subfield code="h">fre</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-29</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC271.C5</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.99/4061</subfield><subfield code="2">21</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3200</subfield><subfield code="0">(DE-625)152888:12905</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Khayat, David</subfield><subfield code="d">1956-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)11361442X</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Cancer chemotherapy treatment protocols</subfield><subfield code="c">David Khayat ; Jonathan Waxman ; Eric-Charles Antoine</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford [u.a.]</subfield><subfield code="b">Blackwell Science</subfield><subfield code="c">1998</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">X, 145 S.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic Agents</subfield><subfield code="x">administration & dosage</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antineoplastic agents</subfield><subfield code="x">Administration</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cancer</subfield><subfield code="x">Chemotherapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Neoplasms</subfield><subfield code="x">drug therapy</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Waxman, Jonathan</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Antoine, Eric-Charles</subfield><subfield code="e">Verfasser</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007846354&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-007846354</subfield></datafield></record></collection> |
| id | DE-604.BV011642285 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-09T18:13:16Z |
| institution | BVB |
| isbn | 0865426937 |
| language | English French |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-007846354 |
| oclc_num | 36470678 |
| open_access_boolean | |
| owner | DE-29 |
| owner_facet | DE-29 |
| physical | X, 145 S. |
| publishDate | 1998 |
| publishDateSearch | 1998 |
| publishDateSort | 1998 |
| publisher | Blackwell Science |
| record_format | marc |
| spelling | Khayat, David 1956- Verfasser (DE-588)11361442X aut Cancer chemotherapy treatment protocols David Khayat ; Jonathan Waxman ; Eric-Charles Antoine Oxford [u.a.] Blackwell Science 1998 X, 145 S. txt rdacontent n rdamedia nc rdacarrier Antineoplastic Agents administration & dosage Antineoplastic agents Administration Cancer Chemotherapy Neoplasms drug therapy Chemotherapie (DE-588)4127083-6 gnd rswk-swf Chemotherapie (DE-588)4127083-6 s DE-604 Waxman, Jonathan Verfasser aut Antoine, Eric-Charles Verfasser aut HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007846354&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Khayat, David 1956- Waxman, Jonathan Antoine, Eric-Charles Cancer chemotherapy treatment protocols Antineoplastic Agents administration & dosage Antineoplastic agents Administration Cancer Chemotherapy Neoplasms drug therapy Chemotherapie (DE-588)4127083-6 gnd |
| subject_GND | (DE-588)4127083-6 |
| title | Cancer chemotherapy treatment protocols |
| title_auth | Cancer chemotherapy treatment protocols |
| title_exact_search | Cancer chemotherapy treatment protocols |
| title_full | Cancer chemotherapy treatment protocols David Khayat ; Jonathan Waxman ; Eric-Charles Antoine |
| title_fullStr | Cancer chemotherapy treatment protocols David Khayat ; Jonathan Waxman ; Eric-Charles Antoine |
| title_full_unstemmed | Cancer chemotherapy treatment protocols David Khayat ; Jonathan Waxman ; Eric-Charles Antoine |
| title_short | Cancer chemotherapy treatment protocols |
| title_sort | cancer chemotherapy treatment protocols |
| topic | Antineoplastic Agents administration & dosage Antineoplastic agents Administration Cancer Chemotherapy Neoplasms drug therapy Chemotherapie (DE-588)4127083-6 gnd |
| topic_facet | Antineoplastic Agents administration & dosage Antineoplastic agents Administration Cancer Chemotherapy Neoplasms drug therapy Chemotherapie |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=007846354&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| work_keys_str_mv | AT khayatdavid cancerchemotherapytreatmentprotocols AT waxmanjonathan cancerchemotherapytreatmentprotocols AT antoineericcharles cancerchemotherapytreatmentprotocols |